Genelux Corporation/$GNLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Ticker
$GNLX
Sector
Primary listing
Employees
26
Headquarters
Website
GNLX Metrics
BasicAdvanced
$127m
-
-$0.85
0.55
-
Price and volume
Market cap
$127m
Beta
0.55
52-week high
$8.54
52-week low
$2.29
Average daily volume
181k
Financial strength
Current ratio
3.679
Quick ratio
3.604
Long term debt to equity
9.507
Total debt to equity
10.885
Profitability
EBITDA (TTM)
-34.375
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-419,762.50%
Operating margin (TTM)
-432,112.50%
Management effectiveness
Return on assets (TTM)
-60.56%
Return on equity (TTM)
-127.28%
Valuation
Price to revenue (TTM)
14,108.911
Price to book
5.52
Price to tangible book (TTM)
5.52
Price to free cash flow (TTM)
-4.036
Free cash flow yield (TTM)
-24.78%
Free cash flow per share (TTM)
-0.706
Growth
Earnings per share change (TTM)
-3.54%
3-year revenue growth (CAGR)
-91.07%
3-year earnings per share growth (CAGR)
-5.35%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs